Can monoamine-based therapies be improved?
Monoamine-based therapies that selectively target serotonin, norepinephrine, or dopamine uptake are effective as antidepressants. However, many depressed patients do not achieve remission with these single-action agents. Treatment strategies that target more than one neurotransmitter, either through augmentation, combination treatment, or the development of single agents with dual or triple reuptake mechanisms, may prove to be even more effective than traditional antidepressants and merit further research.